Skip to main content
. 2016 Oct 25;23(5):e461–e467. doi: 10.3747/co.23.3139

FIGURE 2.

FIGURE 2

Cost-effectiveness acceptability curve for the probabilistic sensitivity analysis. At a willingness to pay threshold of $100,000 per QALY, the addition of bevacizumab to standard chemotherapy is considered a cost-effective treatment alternative to standard chemotherapy alone in ovarian cancer patients who are at high risk of relapse.